Patents Assigned to Forma Therapeutics, Inc.
  • 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors
    Patent number: 9630922
    Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: April 25, 2017
    Assignee: Forma Therapeutics, Inc.
    Inventors: Pui Yee Ng, Heather Davis, Kenneth W. Bair, David S. Millan, Aleksandra Rudnitskaya, Xiaozhang Zheng, Bingsong Han, Nicholas Barczak, David R. Lancia, Jr.
  • Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
    Patent number: 9624175
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: April 18, 2017
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
    Patent number: 9624216
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where Y1, X1, X2, Y2, W1, W2, W3, and R1-R5 are described herein.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: April 18, 2017
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • Benzopiperazine compositions as BET bromodomain inhibitors
    Patent number: 9422281
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) br’omodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R1, R2, R4 and R7 are defined herein.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: August 23, 2016
    Assignee: Forma Therapeutics, Inc.
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot, Mark J. Tebbe
  • Tetrahydroquinoline compositions as BET bromodomain inhibitors
    Patent number: 9388161
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: July 12, 2016
    Assignee: Forma Therapeutics, Inc.
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot
  • Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
    Publication number: 20140163005
    Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are kinase inhibitors, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.
    Type: Application
    Filed: July 24, 2013
    Publication date: June 12, 2014
    Applicant: Forma Therapeutics, Inc.
    Inventors: KRISHNA MURTHI, REBECCA CASAUBON, ARTHUR F. KLUGE, CHASE SMITH, JOACHIM VOGT
  • Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
    Publication number: 20140163223
    Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are kinase inhibitors, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.
    Type: Application
    Filed: July 24, 2013
    Publication date: June 12, 2014
    Applicant: Forma Therapeutics, Inc.
    Inventors: KRISHNA MURTHI, REBECCA CASAUBON, ARTHUR F. KLUGE, CHASE SMITH, JOACHIM VOGT
  • Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
    Publication number: 20140163007
    Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are kinase inhibitors, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.
    Type: Application
    Filed: July 24, 2013
    Publication date: June 12, 2014
    Applicant: Forma Therapeutics, Inc.
    Inventors: KRISHNA MURTHI, REBECCA CASAUBON, ARTHUR F. KLUGE, CHASE SMITH, JOACHIM VOGT
  • Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
    Publication number: 20140163006
    Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are kinase inhibitors, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.
    Type: Application
    Filed: July 24, 2013
    Publication date: June 12, 2014
    Applicant: Forma Therapeutics, Inc.
    Inventors: KRISHNA MURTHI, REBECCA CASAUBON, ARTHUR F. KLUGE, CHASE SMITH, JOACHIM VOGT
  • Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
    Publication number: 20140163222
    Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are kinase inhibitors, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.
    Type: Application
    Filed: July 24, 2013
    Publication date: June 12, 2014
    Applicant: Forma Therapeutics, Inc.
    Inventors: KRISHNA MURTHI, REBECCA CASAUBON, ARTHUR F. KLUGE, CHASE SMITH, JOACHIM VOGT
  • Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
    Publication number: 20140163003
    Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are kinase inhibitors, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.
    Type: Application
    Filed: July 24, 2013
    Publication date: June 12, 2014
    Applicant: Forma Therapeutics, Inc.
    Inventors: KRISHNA MURTHI, REBECCA CASAUBON, ARTHUR F. KLUGE, CHASE SMITH, JOACHIM VOGT
  • Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
    Publication number: 20140163004
    Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are kinase inhibitors, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.
    Type: Application
    Filed: July 24, 2013
    Publication date: June 12, 2014
    Applicant: Forma Therapeutics, Inc.
    Inventors: KRISHNA MURTHI, REBECCA CASAUBON, ARTHUR F. KLUGE, CHASE SMITH, JOACHIM VOGT
  • Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors
    Patent number: 8518958
    Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are kinase inhibitors, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: August 27, 2013
    Assignee: Forma Therapeutics, Inc.
    Inventors: Krishna K. Murthi, Rebecca Casaubon, Arthur F. Kluge, Chase C. Smith, Joachim Vogt
  • Raf inhibitors
    Patent number: 8232283
    Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are inhibitors or kinases such as Raf, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: July 31, 2012
    Assignee: Forma Therapeutics, Inc.
    Inventors: Andreas Schoop, Alexander Backes, Joachim Vogt, Lars Neumann, Jan Eickhoff, Stefan Hannus, Kerrin Hansen, Peter Amon, Igor Ivanov, Matthias Borgmann, Chase Smith, Arthur F. Kluge, Krishan Murthi, Rebecca Casaubon